Merck
ACIP Recommends Capvaxive for Certain Adults Ages 19 and Older
The ACIP unanimously voted to recommend Capvaxive to vaccinate certain adults ages 19 and older to protect against ...
JULY 2, 2024
FDA Approves Capvaxive Pneumonia Vaccine
The FDA approved Capvaxive for adults to prevent against invasive pneumococcal disease and pneumonia caused ...
JUNE 24, 2024
New Indication for Prevymis to Prevent CMV in High-Risk Kidney Transplant Recipients
The FDA granted a new indication for letermovir for prophylaxis of CMV disease in high-risk adult kidney transplant ...
JUNE 6, 2023
Investigational 2-Drug HIV Regimen Appears Safe, Effective
Merck's islatravir is an investigational first-in-class nucleoside reverse transcriptase translocation inhibitor ...
SEPTEMBER 13, 2019
FDA Approves Recarbrio for cUTI and cIAI
The FDA approved Recarbrio to treat adults with complicated urinary tract infections and complicated intraabdominal ...
JULY 17, 2019
Cancer Patients Face Higher Risk for Shingles
People newly diagnosed with cancer, particularly hematologic cancers, and those treated with chemotherapy have a ...
DECEMBER 26, 2018
FDA Approves Delstrigo and Pifeltro for HIV Treatment
The FDA approved Merck’s two doravirine-based HIV-1 medicines: Delstrigo, a once-daily fixed-dose combination ...
AUGUST 30, 2018
FDA Approves New Indication for Lenvima for HCC
The FDA approved a new indication for Lenvima for first-line treatment of patients with unresectable hepatocellular ...
AUGUST 17, 2018
FDA Modifies Indications of Pembrolizumab, Atezolizumab
The FDA modified the urethal cancer indications of Keytruda and Tecentriq, limiting their use to patients who are ...
JULY 3, 2018
New Indications Granted for Keytruda
The FDA granted new indications to Keytruda for the primary mediastinal refractory or relapsed PMBCL and ...
JUNE 19, 2018
Investigational ART Efficacious, Well Tolerated
Doravirine (Merck), a late-stage investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), was found ...
MARCH 9, 2018
HIV Drugs in the Pipeline: Expected Approvals for 2018
Pharmaceutical companies are looking at antiretroviral therapy regimens that are easier on patients with HIV.
FEBRUARY 7, 2018
